Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 2:58 PM
Ignite Modification Date: 2025-12-24 @ 2:58 PM
NCT ID: NCT04884659
Eligibility Criteria: Inclusion Criteria: 1. BMI \>25 kg/m2 2. If taking probiotics during screening, must agree to continue taking them at the same dosage and frequency 3. HbA1C 5.7-6.4% 4. Willing to eat only the food provided 5. Willing to follow the feeding schedule, including fasting for 14 hours/day for 7 days 6. Willing to remain on the RU inpatient 24/7 unit except for weekend passes 7. Normally sleep between the hours of 10 pm and 8 am 8. Weight stable over the last 3 months defined as no more than a 5% change Exclusion Criteria: 1. Diabetes 2. Any intermittent feeding diet within the last 2 weeks 3. HIV positive 4. Hepatitis 5. Self-reported autoimmune diseases (rheumatoid arthritis, SLE (lupus), Crohn's 6. Disease, psoriasis, etc.) 7. Current use of metformin 8. Smoked tobacco within the last 8 weeks 9. Taking any weight loss medication 10. Current use of systemic steroids 11. Allergic to adhesive tape 12. Taking clinically useful medications that contribute to significant weight loss or weight gain ie tricyclic antidepressants, some SSRIs, lithium, antipsychotics, some anticonvulsants, steroids, beta blockers, some antihistamines. 13. Currently pregnant 14. Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT04884659
Study Brief:
Protocol Section: NCT04884659